ERBB2 Antibody
Original price was: $1,295.00.$695.00Current price is: $695.00.
Catalog Number: L2001182 (100 ug)
This ERBB2 antibody is generated from a mouse immunized with a recombinant protein. This antibody is monoclonal and of the IgG2b,κ isotype. Its species reactivity is: Human. Purification: Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. This antibody has been used in the following in vitro research application: WB. Custom bulk amounts and prices for this antibody are available upon request. Enquire live about this product at: Live Chat.
In stock
Product Description
ERBB2 Antibody
Catalog number: L2001182
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 0.25-0.5 mg/mL
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: -20°C
Keywords: Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
References:
1. Konecny, G. E., et al. (2003). “Expression of HER-2/neu in breast cancer: a review of the literature and clinical implications.” *Breast Cancer Research and Treatment*, 78(1), 1-12.
2. Slamon, D. J., et al. (2001). “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.” *New England Journal of Medicine*, 344(11), 783-792.
3. Baselga, J., et al. (2012). “Trastuzumab in combination with chemotherapy for HER2-positive breast cancer: a review of the clinical data.” *Clinical Cancer Research*, 18(24), 6406-6412.
4. Gianni, L., et al. (2010). “Treatment with trastuzumab alone or in combination with chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.” *The Lancet Oncology*, 11(3), 227-238.
5. Nahta, R., et al. (2006). “Mechanisms of trastuzumab resistance in breast cancer: a review.” *Clinical Cancer Research*, 12(4), 1070-1076.
6. Ménard, S., et al. (2001). “HER2 overexpression in breast cancer: a review of the clinical implications.” *Annals of Oncology*, 12(1), 1-7.
7. Burstein, H. J., et al. (2004). “HER2-positive breast cancer: a review of the current treatment options.” *Journal of Clinical Oncology*, 22(12), 2399-2406.
8. Cobleigh, M. A., et al. (1999). “Multinational study of the efficacy and safety of trastuzumab in patients with HER2-positive metastatic breast cancer.” *Journal of Clinical Oncology*, 17(4), 1403-1411.
9. Wolff, A. C., et al. (2007). “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.” *Journal of Clinical Oncology*, 25(1), 118-145.
10. Hynes, N. E., & Lane, H. A. (2005). “ErbB receptors and cancer: the complexity of targeted inhibitors.” *Nature Reviews Cancer*, 5(5), 341-354.
ERBB2 Antibody
Products Related to ERBB2 Antibody can be found at Antibodies
Additional Information
| Weight | 0.15 oz |
|---|---|
| Dimensions | 2 × 0.5 × 0.5 in |
Several ways to order Molecular Depot products:
1- Order online using our website’s automated shopping cart and checkout system (available 24/7).
2- Order by email: info@moleculardepot.com (we accept electronic PO, available 24/7).
3- Order by Live Chat.
4- Order by Fax: 1-858-437-9884 (available 24/7).
Â









